The largest community of pharma leaders

Walden Biosciences Launches to Transform the Treatment of Kidney Disease

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Walden Biosciences, Inc. (Walden), a biotechnology company focused on transforming the treatment of kidney disease, today announced its launch with a $51 million Series A financing led by ARCH Venture Partners and UCB Ventures. Walden is seeking to develop breakthrough medicines that reverse the progression of both rare and common forms of kidney disease and restore renal function. The majority of renal drug development approaches focus on reducing general phy


Recent Articles